107 results
8-K
EX-99.3
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
Chief Operating Chief Scientific Officer & SVP, Sales SVP, Marketing & Chief Administrative Chief Human Head of IR Officer Officer Officer SVP, R&D International
8-K
EX-99.2
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
73% 65% 5% 3% R&D SG&A Adjusted EBITDA $19 margin above 20% $9 $6 to start 2024 -$5 8% % of net sales (7%) 11% 22% Adjusted EBITDA Net Income/Loss 11
8-K
EX-99.1
MDXG
Mimedx Group Inc
28 Feb 24
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
4:22pm
at $13 million compared to 2022. Our R&D expenses in 2022 and 2023 were primarily driven by the development and launches of our newest products
8-K
EX-99.2
uplj1hb30e0livwr
28 Feb 24
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
4:22pm
8-K
EX-99.2
tn3d9j08
13 Nov 23
MIMEDX to Participate in Upcoming Investor Conferences
8:14am
8-K
EX-99.2
2imkwb
30 Oct 23
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
4:05pm
8-K
EX-99.2
270p7t eb3
5 Sep 23
MIMEDX to Present at Upcoming Investor Conferences
8:38am
8-K
EX-99.2
y4pf0 euh5si3
1 Aug 23
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
4:03pm
8-K
EX-99.2
ahy kkptodnverust
2 May 23
MIMEDX Announces First Quarter 2023 Operating and Financial Results
4:06pm
8-K
EX-99.1
ygqvyy
30 Nov 22
Regulation FD Disclosure
7:00am
8-K
EX-99.1
5xf4p pvp4uk5lpk
17 Nov 22
Regulation FD Disclosure
8:01am
8-K
EX-99.2
n8m4qqzex98
2 Nov 22
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
4:22pm